Delving into the Latest Updates on Laboratoire L Lafon with Synapse

Overview

Tags

Nervous System Diseases

Digestive System Disorders

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

COMT(Catechol-O-methyl transferase)	1

In rats, monoamine oxidase inhibition with pargyline suppressed the formation of dihydroxyphenylacetic acid in the striatum and caused the accumulation of dopamine.The effects of the dopamine reuptake inhibitor methylphenidate (stereotyped behavior and an increase in the concentration of extraneuronal dopamine in the striatum) were not decreased by prior monamine oxidase inhibition.These results are not consistent with the hypothesis that (1) transfer of stored dopamine to a releasable site is normally slowed by a high level of free intraneuronal dopamine available from dopamine uptake or synthesis, and (22) blockade of dopamine uptake by methylphenidate, by reducing intraneuronal free dopamine, would remove the feedback inhibition of transfer and accelerate transfer of stored dopamine to neuronally releasable sites.Monoamine oxidase inhibition caused by pargyline may be insufficient to offset the reduction of intraneuronal free dopamine following methylphenidate-induced uptake inhibition.The increase in extraneuronal dopamine levels and the stereotyped behavior seemed to be related only to neurotransmitter accumulation consequent to inhibition of reuptake of released dopamine, without involvement of intraneuronally enhanced dopamine release.

Medicina Experimentalis

Experiments on the teratogenic effect of 2-diethylaminopropiophenone

Author: Cahen, R. ; Pessonnier, Jeanne ; Montagne, Jacqueline ; Sautai, Marguerite

The teratogenic effects of 2-diethylaminopropiophenone were studied in pregnant mice and rats.The compound was either mixed with the diet or given by stomach tube in aqueous solution, dosage 16.25-50 mg./kg. for mice and 7-20 mg./kg. for rats.Most of the animals were sacrificed before term and the fetuses removed.Some animals were kept until the young were weaned and the litter was then examinedDosages in a few experiments were very large, up to 10 times the anorectic dosage and corresponding to 0.1 L.D.₅₀.The compound, in dosages given, did not cause embryopathies or fetal resorption, nor did it reduce the size of the litters.A review with 46 references is given.

Therapie

Effect of DL-2-(3,4-methylenedioxy)phenyl-2-hydroxyacetamidine hydrochloride (LL-1418) on general hemodynamics and cardiac metabolism

Author: Duteil, Jacques ; Boutet, G. ; Bernard, F. ; Assous, E. ; Nadaud, Jacqueline

DL-2-(3,4-methylenedioxy)phenyl-2-hydroxyacetamidine-HCl (LL-1418) (7.5 mg/kg, i.v.) produced a decrease in systemic blood pressure and peripheral resistance without altering cardiac output, general hemodynamics, or myocardial metabolism in anesthetized dogs.At higher dosages (15 mg/kg), LL-1418 decreased the sympathetic tone of the heart, decreasing the myocardial contractile force and left ventricular work.

100 Deals associated with Laboratoire L Lafon

Login to view more data

100 Translational Medicine associated with Laboratoire L Lafon

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Phloroglucin ( COMT )	Muscle Spasticity More	Approved
CRL-41919	Sleep Initiation and Maintenance Disorders More	Pending
CRL-8299	Neoplasms More	Pending
CRL-42482 ( calcium channel )	Angina Pectoris More	Pending